Article Details

Sumitomo Dainippon Pharma inks deal for VR-based DTx with BehaVR

Retrieved on: 2021-10-21 11:53:05

Tags for this article:

Click the tags to see associated articles and topics

Sumitomo Dainippon Pharma inks deal for VR-based DTx with BehaVR. View article details on hiswai:

Excerpt

BehaVR, meanwhile, creates prescription DTx backed by decades of neuroscience and cognitive and evidence-based protocols.

Article found on: www.mobihealthnews.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up